PMID- 37218470
OWN - NLM
STAT- MEDLINE
DCOM- 20230623
LR  - 20230623
IS  - 1751-2441 (Electronic)
IS  - 1751-2433 (Linking)
VI  - 16
IP  - 6
DP  - 2023 Jan-Jun
TI  - Efficacy and safety of compound glycyrrhizin in the patients with vitiligo: a 
      systematic review and meta-analysis.
PG  - 601-611
LID - 10.1080/17512433.2023.2213887 [doi]
AB  - OBJECTIVE: Compound glycyrrhizin (CG) is widely used to treat vitiligo in China, 
      and the efficacy and adverse events (AEs) of CG for vitiligo need further 
      analysis. This study aimed to systematically reevaluate the efficacy and safety 
      of CG in the patients with vitiligo. RESEARCH DESIGN AND METHODS: Eight 
      literature databases were searched up to 31 December 2022, and randomized 
      controlled trials which compared CG plus conventional treatments with 
      conventional treatments alone were included. RESULTS: 17 studies with 1492 
      patients were included. The pooled results showed that the combination of CG and 
      conventional treatments was superior to conventional treatments alone in the 
      total efficacy rate (risk ratio (RR) = 1.54, 95% confidence interval (CI) = 1.40 
      to 1.69, P < 0.00001), cure rate (RR = 1.62, 95%CI = 1.32 to 1.99, P < 0.00001), 
      the levels of serum IL-6, TNF-alpha, IL-17, and TGF-ss, and the ratio of CD4(+)/CD8(+) 
      T cell in blood. Moreover, few patients suffered from the mild and tolerable AEs 
      of CG. CONCLUSIONS: CG plus conventional treatments is an effective treatment for 
      vitiligo with mild and tolerable AEs. More high-quality and large-sample studies 
      are required in the future to provide more evidence of CG for vitiligo. PROSPERO 
      REGISTRATION: CRD42023401166.
FAU - Li, Ming
AU  - Li M
AD  - Department of Dermatology, Beijing Friendship Hospital, Capital Medical 
      University, Beijing, China.
FAU - Xiang, Lujing
AU  - Xiang L
AD  - Department of Dermatology, Beijing Friendship Hospital, Capital Medical 
      University, Beijing, China.
FAU - Li, Yan
AU  - Li Y
AD  - Department of Dermatology, Beijing Friendship Hospital, Capital Medical 
      University, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20230523
PL  - England
TA  - Expert Rev Clin Pharmacol
JT  - Expert review of clinical pharmacology
JID - 101278296
RN  - 6FO62043WK (Glycyrrhizic Acid)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Humans
MH  - *Vitiligo/drug therapy
MH  - Glycyrrhizic Acid/adverse effects
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha
MH  - *Psoriasis
OTO - NOTNLM
OT  - Compound glycyrrhizin
OT  - Efficacy
OT  - Meta-analysis
OT  - Safety
OT  - Vitiligo
EDAT- 2023/05/23 06:42
MHDA- 2023/06/23 06:42
CRDT- 2023/05/23 04:33
PHST- 2023/06/23 06:42 [medline]
PHST- 2023/05/23 06:42 [pubmed]
PHST- 2023/05/23 04:33 [entrez]
AID - 10.1080/17512433.2023.2213887 [doi]
PST - ppublish
SO  - Expert Rev Clin Pharmacol. 2023 Jan-Jun;16(6):601-611. doi: 
      10.1080/17512433.2023.2213887. Epub 2023 May 23.